Avidity Partners Management LP Takes $1.11 Million Position in Abivax SA Sponsored ADR $ABVXMarket Beat·15 hours agoABVX+0.47%MS+0.72%
uniQure (NASDAQ:QURE) Stock Rating Lowered by Wall Street ZenMarket Beat·17 hours agoQURE+3.41%STT+0.73%
Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment DetailsPR Newswire·1 day ago, 03:17 PMTHW+8.00%ASGI+0.34%
Daiichi Sankyo, AstraZeneca Datroway wins EU approval for first-line metastatic TNBC in non-immunotherapy patientsPUBT·1 day ago, 01:30 AMAZN-0.99%DSNKY-11.46%
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy | AZN Stock NewsStockTitan·2 days ago, 05:30 PMAZN-0.99%DSNKY-11.46%
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology pushbiopharmadive·2 days ago, 04:32 PMBIIB-2.40%AZN-0.99%
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga_article·2 days ago, 04:05 PMNUWE-60.90%QURE+3.41%
Abivax says FDA pre-NDA feedback supports planned obefazimod filing by end-2026PUBT·2 days ago, 03:14 PMABVX+0.47%
Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&Dbenzinga_article·2 days ago, 01:45 PMSNY+0.44%
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanksbenzinga_article·2 days ago, 01:37 PMALNY+2.00%AZN-0.99%
Sanofi shares slide after CEO signals challenges to fill drug pipelineMSN·2 days ago, 10:04 AMSNY+0.44%
Regeneron Q2 FY26 GAAP EPS falls 5% to $12.23; revenue rises 17% to $4.3 billionPUBT·2 days ago, 05:37 AMREGN+3.29%SNY+0.44%
SAN: Q2 2026 saw strong sales and profit growth, led by Dupixent and new launchesQuartr·2 days ago, 04:15 AMSNY+0.44%
